TB-500 Research Guide: The Fragment Behind the Name
A clear guide to Hero TB-500: why fragment identity matters, how to read thymosin beta-4 research, and what to verify in laboratory documentation.
Quick facts
| Catalog compound | TB-500 |
|---|---|
| Hero catalog identity | Thymosin beta-4 fragment |
| Hero vial sizes | 5 mg and 10 mg |
| Full-length thymosin beta-4 | 43 amino acids; a distinct material |
| Documentation priority | Confirm sequence and terminal modifications in lot specifications |
| Hero product | TB-500 |
TB-500 is a name that needs a careful definition. Hero’s catalog identifies its TB-500 as a thymosin beta-4 fragment. That distinction matters because full-length thymosin beta-4 and a shorter fragment are different materials, even when online descriptions discuss them together.
Hero Peptides lists TB-500 research material in 5 mg and 10 mg vials. This guide explains the naming issue, places fragment research in context, and identifies what should be verified before applying a published finding to a laboratory sample.
TB-500. View catalog product
Origin story: a fragment and its parent peptide
Full-length thymosin beta-4 contains 43 amino acids. Research on its different regions has explored how particular sequences relate to cellular activities. That broader literature provides context for fragment research, but it does not make every fragment equivalent to the full-length peptide (Sosne et al., 2010).
An analytical study identified an N-terminally acetylated fragment corresponding to residues 17-23 in a product called TB-500. The identified sequence was Ac-LKKTETQ. This is evidence about the preparation examined in that study, not proof of the identity of every product using the same name (Esposito et al., 2012).
For Hero’s material, retain the catalog’s fragment designation and verify the precise sequence and terminal modifications in the lot specifications. The supplied catalog does not independently establish those finer structural details. A familiar product name should not fill that documentation gap.
How fragment research works: structure comes first
A shorter amino-acid sequence contains only part of the parent peptide. Regions removed from the parent may matter to its structure, interactions, or biological behavior. The relevant question is which findings have actually been demonstrated for the exact fragment under study.
The thymosin beta-4 literature discusses actin-related biology and cellular responses. It also examines activities associated with different sequence regions. Read the exact test material beside each result before using that result to motivate a fragment experiment (Sosne et al., 2010).
In a laboratory comparison, define identity before comparing responses. Record sequence, terminal chemistry, stated form, and the amount tested. Equal masses of a short fragment and a full-length peptide do not represent equal molecule counts.
The thymosin beta-4 biology guide covers the parent-peptide background. This guide concentrates on the fragment distinction and on how to avoid carrying unsupported conclusions from one material to another.
Key studies: separate identity from biological effect
| Evidence source | Material or subject | Useful contribution | What it does not establish |
|---|---|---|---|
| Esposito et al., 2012 | A TB-500 preparation and synthesized reference fragment | Analytical characterization of an acetylated 17-23 fragment | Clinical effectiveness or universal product identity |
| Sosne et al., 2010 | Thymosin beta-4 and sequence-region research | Context for structure and biological activity | Equivalence of all fragments and full-length material |
| Lot documentation | The actual supplied sample | Stated identity and analytical results | Unmeasured biological properties |
An analytical identification paper answers what the investigators detected. A biological experiment answers what happened under its test conditions. Both are useful, but they are not interchangeable types of evidence.
When reading a biological paper, examine the methods for the material’s exact identity. If the study used full-length thymosin beta-4, label it that way in a summary. Do not shorten the name to TB-500 simply because a later article treats the words as synonyms.
The BPC-157 comparison addresses another common conflation. These compounds can appear in the same discussion while requiring different hypotheses, analytical expectations, and evidence summaries.
Weak spots: what remains uncertain
FDA’s safety-risk page specifically discusses thymosin beta-4 fragment LKKTETQ, also called TB-500, and identifies limited human safety information and concerns involving aggregation and peptide-related impurities. As of November 17, 2026, this guide does not establish an approved clinical use for Hero’s fragment (FDA, 2026).
The most immediate research limitation is identity ambiguity. A paper, a vendor label, and a discussion forum may use the same shorthand for different preparations. Until the exact structures are matched, an apparent agreement between sources may not be a meaningful comparison.
Another limitation is the transfer of claims across endpoints. A cellular response does not automatically establish tissue-level function, and neither establishes a clinical outcome. Describe the result using the measurement actually performed.
Purity testing also cannot settle every question. A chromatogram and identity analysis should be interpreted within their methods. They do not independently establish stability, sterility, or the response a sample will produce in a new biological model.
Handling TB-500 in the lab
Confirm the material specification before selecting an assay method. If the planned study requires a defined acetylated sequence, verify that requirement against the actual lot documentation. Do not choose a reference mass solely from an unverified product nickname.
For arithmetic only, a nominal 10 mg vial brought to a final volume of 2 mL gives 5 mg/mL. Bringing the same nominal amount to a final volume of 4 mL gives 2.5 mg/mL. A nominal 5 mg amount at a final volume of 2 mL gives 2.5 mg/mL. These calculations describe concentration; they do not establish solvent compatibility or a validated storage interval.
Use the calculator to check unit conversions. Record final volume, solvent, preparation date, and later dilutions, and retain the identity specification with those records. That combination makes the preparation understandable to another researcher.
Hero’s supplied catalog identifies Northfield Analytical as the HPLC and mass-spectrometry testing partner. The COA guide explains why a matching lot number, method, and test scope matter more than a general purity statement.
TB-500 FAQ
Is TB-500 the same as full-length thymosin beta-4?
Hero’s catalog identifies TB-500 as a fragment. Full-length thymosin beta-4 is a distinct 43-amino-acid material, so its findings should not automatically be assigned to the fragment.
Is every product called TB-500 structurally identical?
The name alone does not establish that. Confirm sequence, terminal modifications, and analytical identity for the particular material being studied.
Does an identity test prove biological activity?
No. Identity testing and a functional biological assay answer different questions. A study requiring defined activity needs evidence relevant to that activity.
What is Hero TB-500?
Hero TB-500 is Hero Peptides’ thymosin beta-4 fragment research material in 5 mg and 10 mg vials. Consult the product and lot documentation for the precise supplied specifications.
TB-500. View catalog product
References
- Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4:733-738. Source.
- Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J. 2010;24:2144-2151. Source.
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Current page checked November 17, 2026. Source.
